# Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification

> **NCT00124709** · PHASE4 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1091 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Pimecrolimus
- **DRUG:** Corticosteroid

## Key facts

- **NCT ID:** NCT00124709
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-10
- **Primary completion:** 2008-01
- **Final completion:** 2008-11
- **Target enrollment:** 1091 (ACTUAL)
- **Last updated:** 2011-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124709, "Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00124709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*